Key Points {#FPar1}
==========

Concurrent use of prescription drugs and herbal medicinal products (HMPs) among older adults is substantial, with prevalence varying widely between 5.3 and 88.3%.The most commonly combined prescription medicines were antihypertensive drugs, β-blockers, diuretics, anticoagulants, analgesics, antidiabetics, antidepressants and statins. And the most frequently used HMPs were *Ginkgo biloba*, garlic, ginseng, St John's wort, Echinacea, saw palmetto, evening primrose oil and ginger.There is still limited knowledge of the extent and manner in which older adults combine prescription drugs with HMPs.

Introduction {#Sec1}
============

The world population is ageing. According to the World Health Organization (WHO), by 2050 the population of people aged ≥ 60 years will double and around 400 million people will be ≥ 80 years of age \[[@CR1]\]. By 2040, nearly one in four people (24.2%) in the UK will be aged 65 years or older \[[@CR2]\]. With pharmacotherapy facilitating an ageing population \[[@CR3]\], older populations rely on complex polypharmacy to manage chronic health conditions \[[@CR4]\]. Older adults are the biggest consumers of prescription and over-the-counter (OTC) medicines \[[@CR5]--[@CR7]\], and it is also well-recognised that self- medication \[[@CR8], [@CR9]\] and consumption of non-prescription medicines, particularly herbal and other dietary supplements, is widespread among older adults \[[@CR10]--[@CR16]\]. Polypharmacy \[[@CR17]--[@CR19]\] increases the risks of adverse drug reactions (ADRs) and interactions \[[@CR20], [@CR21]\]. With healthcare systems increasingly burdened with more hospitalisations and prolonged hospital stays due to ADRs \[[@CR22]\], potential herb--drug interactions are major clinical and economic concerns.

In the UK, prescriptions dispensed for those aged over 60 years accounted for 51.2% of the total net cost for all prescriptions in 2014 \[[@CR23]\]. In addition, up to one-quarter of adults use herbal medicinal products (HMPs) \[[@CR6], [@CR24], [@CR25]\]---medicinal products where the active ingredients consist exclusively of herbal substances or herbal preparations \[[@CR26]\]. HMPs are covered by Directive 2001/83/EC on the Community code relating to medicinal products for human use ("Directive on human medicinal products") \[[@CR26]\]. They are mostly bought over the counter, by self-prescription, and are generally not disclosed to healthcare practitioners \[[@CR6], [@CR24], [@CR25]\]. ADRs could occur due to interactions between conventional drugs and HMPs, some of which may have serious consequences \[[@CR15], [@CR27]--[@CR29]\]. For example, St. John's wort (*Hypericum perforatum*) taken with serotonin reuptake inhibitors increases the risk of serotonin syndrome in older adults \[[@CR27]\]. Despite concerns of possible harmful interactions, little is known about the concurrent use of these medicines by older adults.

The aim of this systematic review was to identify and evaluate the literature on concurrent prescription and HMP use among older adults to assess (1) prevalence, (2) patterns, (3) potential interactions and other safety risks, and (4) factors associated with this use.

Methods {#Sec2}
=======

The full review protocol has previously been published \[[@CR30]\]. This review was conducted according to the principles of systematic review \[[@CR31]\] and is reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@CR32]\].

Eligibility Criteria {#Sec3}
--------------------

Literature searches identified studies assessing the prevalence and patterns of concurrent HMPs or herbal dietary supplements used with prescription medicines. Cross-sectional studies, case reports and case series were included. However we excluded PhD theses, editorials, commentaries, in vitro experiments and animal studies. Studies assessing herbal medicine as part of a therapeutic system or system of medicine such as traditional Chinese medicine, Ayurveda, Kampo, Siddha, Unani and homeopathic herbal remedies were also excluded from the review. As were studies assessing the concurrent use of vitamins, minerals and non-herbal dietary supplements or combination products containing herbal and non-herbal substances with prescription medicines.

The WHO defined 'elderly' as individuals over the age of 65 years in developed countries, and over 60 years in developing countries. For the purpose of this review, we have adopted the minimum age of 65 years since the majority of studies identified from our literature searches were conducted in developed countries. Therefore, studies with participants aged 65 years or older, studies with a mean participant age ≥ 65 years, or studies from which data for participants aged ≥ 65 years could be extracted were included in this review.

Search Methods for Identification of Studies {#Sec4}
--------------------------------------------

The following databases were searched until May 2017: Cumulative Index to Nursing and Allied Health Literature (CINAHL) via EBSCO, Cochrane Library, Excerpta Medica database (EMBASE) via OVID, MEDLINE via OVID, the Allied and Complementary Medicine Database (AMED) via EBSCO, PsycINFO via OVID, and Web of Science. Medical Subject Headings (MeSH) and text words included 'herbal medicine', 'prescription drugs' and 'aged'. The scientific names and common names of herbs most documented for concurrent use were applied to ensure a broad search strategy.

No restrictions were placed on language of publication, and reference lists of all identified studies were checked for relevant studies not identified by the electronic searches. Lateral searches were also conducted using the related citation function in PubMed and cited by function in Google Scholar to capture all relevant articles. The search strategy is available as electronic supplementary Appendix S1.

Data Collection and Analysis {#Sec5}
----------------------------

### Selection of Studies {#Sec6}

Retrieved references from all the databases were downloaded into Endnote files and then merged. All duplicate studies were recorded before discarding. Two reviewers (TA and BW) scanned all titles and abstracts for potential relevance. Any article for which there was uncertainty about relevance was retained and the full text assessed. Using a predesigned eligibility checklist, two reviewers (TA and BW) independently assessed full-text articles against the eligibility criteria and recorded an eligibility code. Studies that did not meet the inclusion criteria were excluded and the reasons recorded. Disagreements on eligibility were resolved through discussions between the two reviewers (TA and BW), and the third reviewer (CG) was consulted if no consensus was reached. Full texts of all articles that met the eligibility criteria were obtained and downloaded into Endnote.

### Data Extraction and Management {#Sec7}

A data extraction form was designed for the review, then piloted and amended to ensure that all the required information could be extracted. Data from individual studies were extracted by the first reviewer (TA) using this form, and validated by the second reviewer (BW). Key information extracted included:Publication details: authors, year of publication, country in which the study was conducted.Study design: study type, recruitment and data collection method.Participants: demographic and socioeconomic characteristics, sampling and sample size, previous medical diagnosis, etc.Primary outcomes: prevalence of concurrent use, name and number of HMPs and prescription drugs, pattern of use, and number and types of adverse reactions or potential interactions.Secondary outcomes: disclosure, satisfaction or dissatisfaction, and cost expended on HMPs.Study limitations: response bias, selection bias, representativeness of sample, etc.

### Quality Assessment of Included Studies {#Sec8}

The Joanna Briggs Institute (JBI) checklists for appraising studies reporting prevalence data \[[@CR33]\] and for case reports \[[@CR34]\] were used to screen selected studies prior to inclusion in the review. Two reviewers independently assessed each of the included studies against the criteria on the JBI checklist to minimise bias and establish methodological validity. The JBI checklist for prevalence studies was the preferred assessment tool because it can be used across different study designs reporting prevalence. The checklist also addresses issues of internal and external validity critical to prevalence data. Any disagreements between reviewers were resolved through discussion.

### Data Synthesis {#Sec9}

We used the Evidence for Policy and Practice Information and Co-ordinating Centre (EPPI-Centre) three-stage approach to mixed method research to synthesise data \[[@CR35]\]. A first synthesis was conducted to address the prevalence, pattern of use and patient characteristics associated with concurrent use of HMPs and prescription medicines. The second synthesis focused on safety issues and other factors associated with concurrent use, i.e. disclosure, satisfaction and cost/resources. Finally, using thematic synthesis, we identified key themes and commonalities. Findings were summarised as a narrative account addressing each of the review questions. A detailed discussion of the limitations of the included studies and the implications of our findings was also provided.

Results {#Sec10}
=======

Results of the Search {#Sec11}
---------------------

The literature searches identified 20,837 titles and abstracts. Initial screening of titles and abstracts identified 2199 potentially relevant articles; a total of 2106 articles were excluded for not satisfying all the inclusion criteria. Full texts of the remaining 93 articles were obtained to assess for eligibility. At the end of the eligibility process, 71 articles were excluded for the following reasons: type of intervention (e.g. non-herbal combinations, non-oral; *n* = 9), age (*n* = 24), study type (*n* = 19), and no concomitant use (*n* = 19). Twenty-two studies met our inclusion criteria and were included in this systematic review (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Study selection process

Study Characteristics {#Sec12}
---------------------

Table [1](#Tab1){ref-type="table"} is a summary of included studies, providing information on study setting, sample characteristics, prevalence of concurrent use, and most reported prescription medicines and HMPs, as well as interactions or potential interactions reported from such combinations.Table 1Summary characteristics of the included studies (*n* = 22)Study, countryStudy design/data collection methodSample size, ageDefinition or description of HMPPrevalence of concurrent use (%)Most reported HMPsMost reported prescription medicines^a^Number of potential herb--drug interactions; detailsBatanero-Hernán et al. \[[@CR36]\], SpainCross-sectional survey/semi-structured interview384, ≥ 65 years\
M = 129\
F = 255\
Mean age or range NSNS88.3Chamomile, anise, lime blossom tea, squaw mint or mosquito plant, red tea, valerian, plantago, senna, alder buckthorn, balm mintParacetamol, omeprazole, benzodiazepines, lactulose, antacids, statins, NSAIDs, ventolin, antipsychotics, Alzheimer drugs22; potential risk of haemorrhage from valerian with drugs metabolised by CYP3A4; plantago interferes with the absorption of statins, acenocoumarol, digoxin, paracetamol and metformin, senna with digoxinBlalock et al. \[[@CR38]\], USAPopulation-based epidemiological study/semi-structured interview1423, ≥ 65 years\
Mean age 63 yearsHerbs/natural products, excluding vitamins and minerals19.9Garlic, *Aloe vera*, *Ginkgo biloba,* Echinacea, ginseng, St John's wort, ginger, saw palmettoMetoprolol, atenolol\
Atorvastatin, simvastatin\
Conjugated estrogens\
Omeprazole, lansoprazole\
hydrochlorothiazide, lisinopril, enalapril168; inhibition of CYP3A4 substrates (e.g. atorvastatin, simvastatin) by garlic, *Ginkgo biloba*, Echinacea, St John's wortCanter and Ernst \[[@CR49]\], UKCross-sectional/self-completed questionnaire271, ≥ 50 years\
137, ≥ 65 years\
F = 84 \
M = 53\
Mean age or range NSNSNSGarlic, *Ginkgo biloba*, Echinacea, evening primrose oil, St John's wort, ginseng, *Aloe barbadensis*, devils claw, cranberry, saw palmettoAspirin, bendroflumethiazide, β-adrenoceptor antagonist, HMG-CoA reductase inhibitors, ACE inhibitor, levothyroxine sodium, calcium channel antagonist, proton-pump inhibitorNot possible to extract data for subjects ≥ 65 years of ageDelgoda et al. \[[@CR53]\], JamaicaCross-sectional survey/semi-structured interview365\
32, ≥ 70 years\
Mean age or range NSNSNSDifferent types of mints cerasee, garlic and gingerAtenolol, metformin, ventolin, nifedipine, enalapril, glucophage, hydrochlorothiazide, ranitidine, voltaren, natrilixNSDergal et al. \[[@CR48]\], CanadaCross-sectional survey/semi-structured interview195, ≥ 65 years\
M = 84\
F = 111\
Mean age 73 yearsNatural health products17*Ginkgo biloba*, garlic and EchinaceaAspirin, trazodone, amlodipine, lorazepam*n* = 11 in 9 patients\
Increased risk of bleeding (8), increased risk of coma, enhanced sedative effects of benzodiapines, and blood-pressure medicationDjuv et al. \[[@CR51]\], NorwayCross-sectional survey/self-completed questionnaire381, ≥ 18 years\
32, ≥ 70 years\
Mean age 54.5 yearsNS40Bilberry, green tea, *Aloe vera*, Echinacea, garlic, ginger, *Ginkgo biloba*, cranberryAntihypertensive and diuretics, antihyperlipidemic agents, anticoagulants, analgesics, antihistamines, antidiabetics, antidepressantsNot possible to extract data for subjects ≥ 65 years of ageElmer et al. \[[@CR54]\], USASecondary data analysis/population-based analysis from a cohort study5052, ≥ 65 years\
M = 2009\
F = 3043\
Mean age 75 yearsCAM products9.5Garlic, *Ginkgo biloba*, ginseng, alfalfa, saw palmetto, Echinacea, Aloe vera, St. John's wort, bilberryNSAIDs, warfarin, antihypertensive, statins, omeprazole, nifedipine, furosemide, oral hypoglycaemics*n* = 294; elevated drug effect, decreased drug effect, risk of bleeding, affects blood coagulationIzzo and Ernst \[[@CR16]\], UKSecondary data analysis/systematic review90, ≥ 65 years\
M = 51\
F = 39\
Mean age 68 yearsNSNSSt. John's wort, ginseng, garlic, *Ginkgo biloba* and kavaWarfarin, sertraline, aspirin, caffeine, chlorzoxazone, debrisoquine, midazolam*n* = 47; decreased INR, abnormal bleeding, fatal intracerebral haemorrhage, nausea, anxiety, restlessness, irritabilityKaufman et al. \[[@CR17]\], USACross-sectional, survey/telephone interview2590, ≥ 18 years\
494, ≥ 65 years\
M = 243\
F = 251\
Mean age or range NSDietary supplements16Ginseng, *Ginkgo biloba*, garlic, St. John's wort, Echinacea, saw palmettoAcetaminophen, ibuprofen, aspirin, conjugated estrogens, lisinopril, atenolol, levothyroxine sodium, hydrochlorothiazide, furosemide, atorvastatin, calciumNot assessedLantz et al. \[[@CR39]\], USACase reports5, ≥ 65 years\
F = 2 \
M = 3\
Mean age 77.4 yearsDietary supplementNSSt. John's wortSertraline, calcium carbonate, conjugated estrogens aspirin, multivitamin, cyproheptadine, nefazodone*n* = 5; central serotonergic syndromeLoya et al. \[[@CR40]\], USACross-sectional survey/semi-structured interviews130, ≥ 65 years\
M = 30\
F = 100\
Mean age 71.4 yearsNS34.6Chamomile tea, garlic, flaxseed, artemisia tea (wormwood), *Ginkgo biloba*Aspirin, metformin, paracetamol, atorvastatin, levothyroxine sodium, hydrochlorothiazide, alendronic acid, metoprolol, lisinopril, losartan*n* = 220; the majority had potential to result in alterations in either blood glucose or blood pressureLy et al. \[[@CR41]\], USACross-sectional survey/self-completed questionnaire123, ≥ 65 years\
M = 98\
F = 25\
Mean age 78 yearsNS22.8Garlic, *Ginkgo biloba*, saw palmetto, Echinacea, ginsengAntihypertensives, antidiabetic drugs, aspirin or another NSAID, corticosteroids*n* = 5; four involved *Ginkgo biloba* and aspirin, one involved garlic and warfarin. All can increase the risk of bleedingNahin et al. \[[@CR42]\], USACross-sectional survey/self-completed questionnaire3072, ≥ 75 years\
M = 1653\
F = 1419\
Mean age or range NSDietary supplement83Garlic, *Ginkgo biloba*, saw palmetto, Echinacea,Aspirin, statin, β-blocker, ACE inhibitors, NSAIDs, thyroid agents, oestrogen, cyclooxygenase-2 inhibitor, thiazide diuretics, vasodilatorsNSParkman \[[@CR43]\], USACase reportM = 1, 68 yearsNSGinseng, *Ginkgo biloba*, valerianCoumadin (warfarin)*n* = 3; nosebleeds, bruises on shins and forearms, and serious headachePeklar et al. \[[@CR50]\], IrelandCross-sectional survey/face-to-face interviews8081, ≥ 50 years\
3446, ≥ 65 years\
M = 3706\
F = 4375\
Mean age 63.8 yearsDietary supplement14Evening primrose oil, garlic, ginsengBisphosphonates, antineoplastic drugs, other analgesics, antiarrhythmic, opioid analgesics*n* = 5; increased risk of bleeding from evening primrose, garlic and ginseng combined with an antithromboticPeng et al. \[[@CR44]\], USACross-sectional survey/self-completed questionnaire458\
260, ≥ 65 years\
M = 244\
F = 16\
Mean age or range NSDietary supplement38Garlic, *Ginkgo biloba*, saw palmetto, ginseng, St. John's wort, DHEA supplements (soy, wild yam), Echinacea,Ibuprofen, fluoroquinolone, levofloxacin, warfarin, hydrochlorothiazide, digoxin, fosinopril sodium, lisinopril, paroxetine*n* = 48; increased risk of bleeding due to lowered platelet aggregation, effectiveness of diuretic lowered, lowered anticoagulant effect, increased serotonin levelsQato et al. \[[@CR5]\], USACross-sectional survey/interviews2976, ≥ 57 years\
1960, ≥ 65 years\
M = 920\
F = 1040\
Mean age or range NSNS52Saw palmetto, flax, garlic, *Ginkgo biloba*Aspirin, hydrochlorothiazide atorvastatin, levothyroxine, lisinopril, metoprolol, simvastatin, atenolol, amlodipine, metformin*n* = 12; increased risk of bleedingShane-McWorter and Geil \[[@CR37]\], USACase reports2, ≥ 52 years\
M = 1, 72 yearsNSSt. John's wort, Asian ginsengMetformin, nateglinide, rosiglitazone, losartan, warfarin, digoxin, atorvastatin, paroxetine, acetaminophen*n* = 3; reduced blood pressure-lowering effect, decreased INR, decreased digoxin effectSingh and Levine \[[@CR47]\], CanadaCross-sectional survey/telephone interviews11, 424, ≥ 18 years\
Mean age or range NSNatural health product5.3Echinacea, garlic, evening primrose oil, *Ginkgo biloba*, ginseng, flax seed oil, St John's wort, apple cider vinegarASA, statins, NSAIDs, calcium channel blockers*n* = 124; increased bleeding risk, increased blood pressure reduction, reduced drug level, reduced glucose controlTurkmenoglu et al. \[[@CR52]\], TurkeyCross-sectional survey/semi-structured interview1418, ≥ 65 years\
M = 462\
F = 956\
Mean age or range NSNS63.3Lime, nettle, sage, mint, thyme, flaxseed, linseed, senna, green tea, rosehip, chamomileCardiovascular, digestive and metabolism drugs, musculoskeletal, nervous system drugs, haematopoietic, systemic hormonal drugs, respiratory system drugsNot assessedYoon and Horne \[[@CR45]\], USACross-sectional survey/semi-structured interviewF = 86, ≥ 65 years\
Mean age 74.9 yearsNS45.3*Ginkgo biloba* or combinations, garlic and clovesMultivitamins, calcium, vitamin E, vitamin C, aspirinNot assessedYoon and Shaffer \[[@CR46]\], USASecondary analysis of dataF = 58, ≥ 65 years\
Mean age 75.6 yearsNSNSGarlic, *Ginkgo biloba*, ginseng, St. John's wortIbuprofen, ASA, nabumetone, estrogen, progesterone, amlodipine, fentanyl, albuterol, warfarin, ticlopidine*n* = 43; increased risk of GI bleeding, metabolism of calcium inhibited, antidiabetic activity, decreased contraceptive or hormone replacement efficacy*ASA* acetylsalicylic acid, *NSAIDs* non-steroidal anti-inflammatory drugs, *ACE* angiotensin-converting enzyme, *HMG-CoA* 3-hydroxy-3-methyl-glutaryl-coenzyme A, *CAM* complementary and alternative medicine, *INR* international normalised ratio, *GI* gastrointestinal, *M* male, *F* female, *NS* not stated, *HMP* herbal medicinal product, *DHEA* dehydroepiandrosterone, *CYP* cytochrome P450^a^Ten most commonly reported

All included studies were published in the English language, except one study published in Spanish \[[@CR36]\]. Thirteen of the included studies were conducted in the USA \[[@CR5], [@CR17], [@CR37]--[@CR46], [@CR54]\], two in Canada \[[@CR47], [@CR48]\] and two in the UK \[[@CR16], [@CR49]\]. Only one study each was conducted in Ireland \[[@CR50]\], Norway \[[@CR51]\], Turkey \[[@CR52]\], Spain \[[@CR36]\] and Jamaica \[[@CR53]\]. The majority of studies (*n* *=* 16) were described as cross-sectional \[[@CR5], [@CR17], [@CR36], [@CR38], [@CR40]--[@CR42], [@CR44], [@CR45], [@CR47]--[@CR53]\], eight of which identified concurrent use of prescriptions with other medications using semi-structured interviews \[[@CR17], [@CR36], [@CR38], [@CR40], [@CR45], [@CR47], [@CR52], [@CR53]\]; others interviewed older people, and then checked and recorded their medications \[[@CR5], [@CR17], [@CR42], [@CR48], [@CR50], [@CR54]\]. Self-completed questionnaires were adopted in five studies \[[@CR41], [@CR42], [@CR44], [@CR49], [@CR51]\], with participants self-reporting on the questionnaire all the medicines they were taking. Three studies \[[@CR16], [@CR46], [@CR54]\] were secondary analyses of data from previous research and three were case reports \[[@CR37], [@CR39], [@CR43]\] of possible interactions between herbal dietary supplements and prescription medicines. Only four studies have been published in the last 5 years \[[@CR36], [@CR50]--[@CR52]\]. Seventeen studies were published between 2000 and 2010, and one case report was published in 1999 \[[@CR39]\].

The 22 studies included in this review had a total of 18,399 participants aged 65 years or over. The average age of participants ranged from 63 to 78 years, and the number of participants ranged from one (case report) to 5052. Only in ten studies was the focus on those aged 65 years or older, with the other studies conducted among the general population aged ≥ 18 years, but data for participants aged ≥ 65 years could be extracted.

Participants were predominantly females in 12 studies, varying between 51% \[[@CR17]\] and 100% \[[@CR46], [@CR55]\]. Male participants were the majority in five studies \[[@CR16], [@CR41]--[@CR44]\]. The number of males and females in the different age categories were not specified in four studies \[[@CR38], [@CR47], [@CR51], [@CR53]\]. One study each was conducted among older adults in hospitals \[[@CR52]\] and nursing homes \[[@CR36]\]. The remaining studies were conducted among general populations (i.e. community-dwelling older adults) \[[@CR5], [@CR16], [@CR17], [@CR37]--[@CR41], [@CR46], [@CR47], [@CR49]--[@CR51], [@CR53], [@CR55]\], outpatients of memory clinics \[[@CR42], [@CR48]\], emergency department \[[@CR43]\] and veteran centre \[[@CR44]\].

We ensured only studies that actually evaluated HMPs were included by looking at the definition where provided and the herbal medications reported. However, no consistent term exists for HMPs and different terms are used in different countries. For example, in Canada, HMPs are referred to as natural health products (NHPs), i.e. "Substances or combination of substances consisting of molecules and elements found in nature and homeopathic preparations sold in dosage forms for the purpose of maintaining or improving health, and treating or preventing diseases/conditions, and includes herbal medicines, vitamins and minerals" \[[@CR56]; p. 2\]. Both Canadian studies included in this review \[[@CR47], [@CR48]\] used the term 'natural health products'. Only one study from the US \[[@CR38]\] used 'herbs/natural products', but excluded vitamins and minerals.

Elmer et al. \[[@CR54]\] used the term complementary and alternative medicine (CAM) products, defined as "products such as herbal (botanical) products or non-botanical dietary supplements (e.g. glucosamine) excluding vitamins and minerals". Five studies \[[@CR17], [@CR39], [@CR42], [@CR44], [@CR50]\] used the definition of dietary supplement according to Directive 2002/46/EC of the European Parliament and of the Council, 2002 \[[@CR26]\], i.e. "potentially any product intended for ingestion as a supplement to regular diet, including vitamins or minerals (at any dose level), herbal products, and nutraceuticals". Twelve studies \[[@CR5], [@CR16], [@CR37], [@CR40], [@CR41], [@CR43], [@CR46], [@CR49], [@CR51]--[@CR53], [@CR55]\] provided no definition or an explanation of HMP. All potentially eligible studies were therefore individually screened to ensure they met this inclusion criterion independent of the definition used.

Synthesis of Results {#Sec13}
--------------------

### Prevalence of Concurrent Prescription Drugs and Herbal Medicinal Products (HMPs) Among Older Adults {#Sec14}

Fifteen studies reported prevalence of concurrent use, while no such information was provided in four articles \[[@CR16], [@CR46], [@CR49], [@CR53]\] and three were case reports where prevalence cannot be calculated \[[@CR37], [@CR39], [@CR43]\]. Prevalence of concurrent use varied widely between 5.3% \[[@CR47]\] and 88.3% \[[@CR42]\].

Table [1](#Tab1){ref-type="table"} shows the most concurrently combined prescription medicines and HMPs from the included studies. The common groups of prescription medicines concurrently combined with HMPs were antihypertensive drugs, β-blockers, diuretics, antihyperlipidemic agents, anticoagulants, analgesics, antihistamines, antidiabetics, antidepressants and statins.

The most commonly used HMPs as reported in the included studies were Ginkgo (*Ginkgo biloba*), garlic (*Allium sativum*), Ginseng (*Panax ginseng*), St John's wort (*Hypericum perforatum*), Echinacea (*Echinacea purpurea*), saw palmetto (*Serenoa repens*), evening primrose oil (*Oenothera biennis*) and ginger (*Zingiber officinale*). In some studies, non-herbal dietary or nutritional supplements \[[@CR37], [@CR41], [@CR42], [@CR47], [@CR49], [@CR50]\], vitamins and minerals \[[@CR17], [@CR42], [@CR44], [@CR50]\] and OTC conventional medicines \[[@CR40], [@CR48], [@CR53], [@CR54]\] were also concurrently used by participants in addition to prescription drugs and HMPs. In one study \[[@CR42]\], 82.5% of participants receiving prescription medicines also used at least one non-herbal dietary supplement, while 54.5% used three or more.

### Potential Interactions and Safety Issues {#Sec15}

Potential interactions from reported combinations of prescription drugs and HMPs were evaluated using different methods. Some studies used a combination of two or more of the following methods: review of possible interactions from previously published clinical data, case reports and textbooks \[[@CR16], [@CR41], [@CR42], [@CR47], [@CR51], [@CR54]\], and comprehensive online databases such as Micromedex (<https://www.micromedexsolutions.com>), Natural Medicines (<https://naturalmedicines.therapeuticresearch.com/>, formerly Natural Standard) and Stockley's Drug Interactions (<http://www.pharmpress.com/product/MC_STOCK/stockleys-drug-interactions>) \[[@CR5], [@CR40], [@CR42], [@CR44], [@CR46], [@CR50]\].

Due to how data were presented in two studies \[[@CR49], [@CR51]\], it was not possible to extract potential interactions for participants aged ≥ 65 years. No evaluation of potential interactions was done in five studies \[[@CR17], [@CR42], [@CR45], [@CR52], [@CR53]\], while a total of 1010 individual interactions or potential interactions were reported in 15 studies. The potential risks of bleeding due to the use of *Ginkgo biloba*, garlic or ginseng with aspirin and warfarin were the most reported \[[@CR5], [@CR36], [@CR37], [@CR41], [@CR43], [@CR44], [@CR46], [@CR48], [@CR50], [@CR54]\], or with other antithrombotic drugs \[[@CR50]\]. Other interactions reported included the risk of decreased international normalised ratio (INR) \[[@CR16], [@CR37]\], alterations in either blood glucose or blood pressure \[[@CR40]\], nausea and dizziness \[[@CR39]\], anxiety \[[@CR16]\], headaches \[[@CR39], [@CR43]\], restlessness and irritability \[[@CR16]\]. An important and risky mode of herb--drug interaction is the inhibition of cytochrome P450 3A4 substrates (e.g. atorvastatin, simvastatin, amlodipine, verapamil) by garlic, *Ginkgo biloba*, Echinacea and St John's wort \[[@CR38]\]. For example, St. John's wort could reduce the blood pressure-lowering effect of losartan, or decrease the effects of digoxin \[[@CR37]\].

Interactions were rated by the authors as 'major or high risk', 'moderate' or 'minor'. The majority of potential interactions reported in the included studies were minor and of unknown clinical significance or uncertain risk for an adverse interaction \[[@CR16], [@CR54]\]. These interactions were cited in the literature based only on theoretical evidence \[[@CR47]\]. Potential major herb--drug interactions reported were between non-steroidal anti-inflammatory drugs (NSAIDs) and *Ginkgo biloba*, resulting in an increased risk of gastrointestinal bleeds due to decreased platelet aggregation \[[@CR46]\]. Other major interactions occurred between drugs and non-herbal supplements \[[@CR50]\], or involved the use of non-prescription drugs \[[@CR5]\].

### Concurrent Use and Associated Factors {#Sec16}

The majority of studies included in this review did not assess concurrent use with demographic or clinical variables. For the 11 studies that assessed demographic or clinical factors \[[@CR5], [@CR17], [@CR38], [@CR45], [@CR47], [@CR49]--[@CR54]\], the following can be summarised:

#### Ethnicity {#Sec17}

Only one study assessed the differences in concurrent use between different ethnic groups. African Americans used significantly more garlic (*p* = 0.003), although no significant difference was observed in the use of ginseng or *Ginkgo biloba* between African Americans and White participants \[[@CR54]\].

#### Sex and Age {#Sec18}

An important sex difference in medication use among older adults was observed in seven studies \[[@CR5], [@CR17], [@CR38], [@CR47], [@CR49]--[@CR51]\]. Women used more herbal supplements than men \[[@CR5], [@CR49]\], while a significantly higher prevalence of use of five or more prescription medications among women aged 57 through 64 years was reported in two studies \[[@CR5], [@CR17]\]. Consequently, more women than men concurrently use HMPs with prescription medicines \[[@CR5], [@CR38], [@CR50], [@CR51]\]. Qato et al. \[[@CR5]\] found up to 60% of women in the oldest age groups used prescription medications in combination with herbal dietary supplements. Furthermore, increased odds for a co-user to be female (34 vs. 18%, *p* = 0.001) and older (more than one in every three were older than 50 years of age) was also confirmed by Djuv et al. \[[@CR51]\].

Two studies \[[@CR45], [@CR50]\] found no association between age and concurrent use. Singh and Levine \[[@CR47]\] reported that older users who combined prescriptions with NHPs, and females, were more likely to have potential interactions than males who combined prescriptions with NHPs (63 vs. 48%).

#### Disease State or Clinical Condition {#Sec19}

Five studies \[[@CR47], [@CR50]--[@CR53]\] compared concurrent use with disease state or clinical conditions. Herbal product use was slightly higher among participants who experienced ongoing health problems (31.1%) than healthy older adults (24.9%), although the difference was not significant. Consequently, herbal product use was significantly higher among participants who reported continuous drug use compared with those who did not use any drugs \[[@CR52]\]. Increased levels of co-use were associated with the use of analgesics or a dermatological drug \[[@CR51]\], and chronic diseases were associated with an increased likelihood of concurrent prescription and supplement use \[[@CR50]\]. High blood pressure and diabetes were also strongly associated with potential interaction \[[@CR47]\]. However, Delgoda et al. \[[@CR53]\] found no significant association between concurrent herb--drug use and a participant's disease.

#### Education and Household Income {#Sec20}

Only four studies \[[@CR47], [@CR50], [@CR52], [@CR53]\] assessed the educational level or household income of participants with concurrent use. Concurrent herb--drug use was greater among individuals who had an education no higher than secondary level \[[@CR50], [@CR53]\], and higher education was associated with a lower probability of potential interaction \[[@CR47]\]. Therefore, compared with post-secondary graduates, participants with less than a high-school education were 70% more likely to exhibit at least one potential interaction \[[@CR47]\].

The prevalence of concurrent herb--drug use was also greater among individuals from households with a lower household income or with no form of health insurance \[[@CR53]\]. Having private medical insurance was associated with an increased likelihood of using HMPs \[[@CR50]\]; however, Turkmenoglu et al. \[[@CR52]\] found no significant associations between HMP use and income.

#### Disclosure of HMP Use to Healthcare Professionals {#Sec21}

Only six of the included studies asked participants if the use of HMPs was disclosed to their doctors or other healthcare professionals \[[@CR41], [@CR44], [@CR45], [@CR51]--[@CR53]\]. No distinct trend was observed among the six studies and disclosure varied widely between 12% \[[@CR52]\] and 78% \[[@CR44]\]. A study of 1418 older adults \[[@CR52]\] reported that 42.2% (*n* *=* 180) of concurrent users believed herbal products were not harmful and therefore did not need to discuss these with their healthcare providers. Although 51 participants (12%) always reported herbal use to their physician, 40% (*n* = 169) would only disclose herbal product use to healthcare providers if asked, and 2.8% (*n* *=* 12) would only disclose herbal product use if they had a problem. In another study \[[@CR44]\], 78% of participants reported HMP use, although 58 of the 99 concurrent users said they were not questioned by healthcare practitioners on their HMP use. Approximately 64% of co-users (*n* = 18) of HMPs and prescription drugs disclosed use in one study \[[@CR41]\], while in another study, almost 80% of users of HMPs did not disclose use \[[@CR51]\].

#### Expenditure on HMPs and Satisfaction {#Sec22}

Only two studies conducted in the US in 2002 and 2004 \[[@CR41], [@CR44]\], respectively, considered the cost or resources spent on HMPs by older adults. The majority of concurrent users (64 and 83%) spent \$25 or less on HMPs per month, approximately 15% spent between \$25 and \$50 per month \[[@CR44]\], and only 3 of 28 (11%) \[[@CR41]\] and 1 of 99 (1%) \[[@CR44]\] concurrent users spent more than \$100 per month on HMPs.

Quality Appraisal {#Sec23}
-----------------

Considering the paucity of research in this area, a cut-off score of 4 was accepted for each JBI checklist to ensure there were sufficient studies to review while maintaining the strength of methodological quality. Typically, research in this area is not randomised; a score of 7 and above indicated high quality, while a score of 4--6 indicated moderate quality. All 22 studies were of sufficient quality and were included in this review.

Discussion {#Sec24}
==========

This systematic review included a total of 22 studies that investigated concurrent use of prescription medicines with HMPs. The majority of studies were conducted in the US, with only four of the studies being conducted in the last 5 years. It can be concluded from the results presented that the prevalence of concurrent prescription and HMP use among older adults is substantial. The most commonly combined prescription drugs by older adults are antihypertensive drugs, β-blockers, diuretics, antihyperlipidemic agents, anticoagulants, analgesics, antihistamines, antidiabetics, antidepressants and statins. And the HMPs most commonly combined include *Ginkgo biloba*, garlic, ginseng, St John's wort, Echinacea, saw palmetto, evening primrose and ginger. Furthermore, there are demographic and clinical factors associated with concurrent prescription and HMP use. Women, as well as individuals in the oldest age groups, with chronic conditions, less than a high-school education and receiving a low income, are more likely to be concurrent users. The most common potential interaction was the risk of bleeding from combinations of *Ginkgo biloba*, garlic or ginseng with aspirin and warfarin, all of which are frequently used by older adults.

The included studies varied greatly in terms of participants, products and outcome measures. Generic terms such as 'elderly' or 'older persons' are commonly used \[[@CR57]\], but there is no concrete definition of these terms. While ageing is an inevitable process measured by chronological age, its impact varies across populations \[[@CR58]\]; therefore, different definitions and chronological age are adopted in clinical studies. While some authors regarded 'older adults' or 'elderly' as those aged 65 years and older, others used the cut-off point of 60 years, or even 75 years, which affected both how participants were grouped and the synthesis of data. Furthermore, many studies looked at adult populations including 'older adults' or 'elderly', but did not, or only partially, report results separately for this age group. In the latter case, only results that were clearly reported for adults aged 65 years and older were included in our analysis. We therefore had to exclude a number of potentially relevant articles due to either a lack of definition or separate reporting.

The heterogeneity in definitions adopted for HMPs and the inconsistencies on what is included as an HMP demonstrates the lack of precision around what may or may not be seen as an HMP. While one study \[[@CR54]\] adopted the term 'complementary and alternative medicine', excluding vitamins and minerals, other studies adopted the terms 'natural health product' and 'dietary supplements', including both vitamins and minerals. Moreover, many did not differentiate between HMPs and dietary supplements, but rather included all types of medications, including vitamins, minerals, and herbal and non-herbal dietary supplements. We only included studies of HMPs that were explicitly named in the Results section. This variation did not allow for comparisons across studies to be conducted, and also blurred what might be seen as nutritional interventions to improve overall health and those that are used explicitly for medicinal purposes to address specific medical conditions.

The prevalence of concurrent prescriptions and HMP use among adults aged 65 years and older ranged from 5.3 to 88.3%. Several factors might explain the discrepancies in the prevalence of concurrent use reported in studies included in this review. First, variation in the range of prevalence reflected the different definitions, types of HMPs assessed, and participants. Second, many of the studies relied on patient recall of the prescription and herbal medicines they use, possibly resulting in recall bias. In some studies \[[@CR5], [@CR17], [@CR42], [@CR48], [@CR50], [@CR54]\], participants took bottles and containers of medicines they were taking along to interviews, for documentation by the research teams.

One of the outliers, an analysis of the 2000--2001 Canadian National Population Health Survey, reported only 5.3% concurrent use of NHPs with prescription medications \[[@CR47]\]. This difference in prevalence may be explained by underreporting or recall bias due to how the data were collected. Participants were asked for the medications and NHPs used in the previous 24 h. This is unusual compared with other surveys on this topic where current and previous use over 2 weeks \[[@CR42]\] and up to 12 months was requested \[[@CR38], [@CR41], [@CR49]\]. Therefore, the data may have revealed only a percentage of respondents exposed to an NHP during a limited time period. In addition, herbs and other NHPs are widely used in a variety of foods, beverages, and multivitamin supplements, but because these were not specifically asked about in the survey, it is possible that their use was not reported. Therefore, the true prevalence of concurrent prescription--NHP interactions in the study population may be higher than reported.

The other outlier is a Spanish study that reported a prevalence of concurrent use of 88.3%. The study assessed both commercially prepared HMPs and home remedies concurrently used with prescription medicines among community-dwelling older adults and those resident in care homes. All medicinal plants, including teas and spices, widely consumed in Spain were included in the analysis, which may have contributed to the high prevalence rate recorded in this study.

Three \[[@CR5], [@CR42], [@CR45]\] of the five studies \[[@CR5], [@CR36], [@CR42], [@CR45], [@CR52]\] with the highest prevalence rates, ranging between 45.3 and 83%, were conducted in the US. These high prevalence rates could be due to the healthcare system or the sociocultural characteristics of the location where research was conducted. For the American studies, patients potentially used HMPs and non-prescription drugs for prevention or self-treatment \[[@CR45]\] as alternatives to expensive medical consultations and prescription drugs. Second, only one \[[@CR42]\] of the five studies provided a definition of what is regarded as an HMP. Considering the inconsistencies in what HMPs include, it is possible that other non-herbal dietary products were considered.

Demographic characteristics, as well as health status, have been associated with the use of herbal medicines and natural products. Sex, age, ethnicity and health status may result in greater use of herbs and natural products \[[@CR38]\]. Although only 50% of the studies included in this review compared demographic characteristics and health status with concurrent use, the results confirm earlier findings \[[@CR11]\] that the use of herbal medicines varies widely between countries and ethnic groups. For example, the two Canadian studies \[[@CR47], [@CR48]\] reported lower rates compared with studies from the US. In addition, the rate of combining prescription medications and dietary supplements was higher among women than men across all age groups \[[@CR5], [@CR17]\]. These trends were also reported in earlier studies \[[@CR59], [@CR60]\].

Sex differences in concurrent use among older adults may be explained by the higher prevalence of chronic conditions among women compared with men \[[@CR61]\]. Concurrent use was greater among older adults from households with a lower household income, no health insurance and no post-secondary education, which may be due to the type of healthcare system, i.e. paid for or free at the point of delivery. It is therefore reasonable to assume that in such countries, participants may rely more on HMPs, or use them as alternatives to expensive medical consultations.

Although there is increased awareness of interactions between conventional drugs and HMPs, the lack of agreement about how to identify HMPs or rigorous clinical evidence hinders researchers, clinicians and consumers in making informed decisions about safe combinations of conventional drugs and HMPs \[[@CR62]\]. The majority of the evidence on herb--drug interactions is from case reports. Arguably, the scarcity and poor quality of primary research may mean that interactions of serious consequences associated with concurrent use of HMPs are unknown and unrecognised \[[@CR63]\]. The evidence from this review would suggest that there is potential for harm.

There is a potentially high rate of unreported use of HMPs among older adults. Only 28% of included studies asked participants if the use of HMPs was disclosed to healthcare professionals. Our findings confirm previous research \[[@CR64]--[@CR66]\] that only approximately one-third of HMP users disclose use to healthcare professionals. Disclosure of herbal medicine use is crucial to avoiding herb--drug interactions and non-adherence to prescription medications. The reasons for non-disclosure of HMP use, as reported in this review and confirmed by other studies, includes a perceived negative attitude of clinicians to complementary medicine use \[[@CR66], [@CR67]\], clinicians do not ask \[[@CR66], [@CR68], [@CR69]\], and the notion that HMPs are 'harmless' \[[@CR68]\].

Limitations {#Sec25}
-----------

The main limitation of this review is the heterogeneity or non-definition of HMPs in available studies, which prevented a meta-analysis. Second, we had to exclude a large number of studies because either the use of HMPs was unclear or results reported were not age-specific to enable us to extract data for subjects aged ≥ 65 years. Finally, only four of the included studies were published in the last 5 years \[[@CR36], [@CR50]--[@CR52]\]; 17 were published between 2000 and 2010, and one case report was published in 1999 \[[@CR39]\]. The increasing use of HMPs worldwide could mean that the review underestimates the range and scale of the issues.

Implications for Practice {#Sec26}
-------------------------

Evidence from this review indicates that a large number of older adults concurrently use prescription drugs and HMPs, and the majority do not disclose this to healthcare practitioners. However, the findings do demonstrate that certain combinations of prescription drugs and HMPs can have serious consequences. Therefore a better understanding of the extent and manner in which older adults combine prescription drugs and HMPs in their health regimens, and the associated risks, is important for healthcare practitioners.

Conclusions {#Sec27}
===========

The prevalence of concurrent use of prescription drugs and HMPs by older adults is generally substantial, although variations in the extent of use are reported. These variations can be explained by methodological factors, including definition of HMPs, participant selection, sociodemographic factors and differences in healthcare systems. Concurrent use of prescription drugs and HMPs is associated with risks, some with potentially serious consequences. The most reported interactions in older adults were risk of bleeding due to the use of *Ginkgo biloba*, garlic or ginseng in combination with aspirin and warfarin or other antithrombotic drugs. Underreporting is substantial and adds to the problem, considering that in most countries there are no appropriate safeguards to minimise the potential harm. By identifying the most commonly used combinations, healthcare professionals, including pharmacists, can be informed on how to appropriately identify and manage patients at risk. It also highlights the need for targeted patient information provided by healthcare professionals and pharmacists as part of routine consultations. Further research is needed to explore why older people use HMPs alongside their prescribed medication, and how their decisions regarding preferred treatments can be documented and discussed by prescribing clinicians, in order to identify and manage the potential risk of herb--drug interactions.
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